Vir Biotechnology, Inc. (VIR) Stock Forecast
VIR analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 9 analysts
- Price target
- $21.00 average of analyst targets
- Upside to target
- +110.8% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.80
- 52-week range
- $5.12 – $11.78
VIR analyst ratings
9 analystsNumber of analysts at each rating.
VIR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
VIR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.73 | −$0.95 | −$0.58 | −$1.17 | +37.5% | 7 |
| Current fiscal year (2026) | −$1.76 | −$2.22 | −$1.37 | −$3.16 | +44.5% | 7 |
| Next fiscal year (2027) | −$2.49 | −$2.94 | −$1.57 | −$1.76 | −41.7% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
VIR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $987,290 | $0 | $2.8M | +311.4% | 7 |
| Current fiscal year (2026) | $245.2M | $238.9M | $259.3M | +257.7% | 9 |
| Next fiscal year (2027) | $76.1M | $2.0M | $183.5M | −69.0% | 8 |
VIR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
VIR revenue: reported and forecast
VIR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.81 | −$0.75 | −$0.73 | −$0.73 | −$0.73 | −9.3% | 2 up · 2 down |
| Current fiscal year (2026) | −$1.37 | −$1.78 | −$1.76 | −$1.76 | −$1.76 | +27.8% | 0 up · 4 down |
| Next fiscal year (2027) | −$2.32 | −$2.49 | −$2.49 | −$2.49 | −$2.49 | +7.1% | 1 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
VIR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; VIR beat in 4 of 12.
What analysts expect from VIR
9 analysts cover Vir Biotechnology; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $21.00, 110.8% above the latest close of $9.96. Analysts expect earnings of −$1.76 per share for 2026, +44.5% from a year earlier. For 2027 the average estimate is −$2.49 per share on revenue of $76.1 million. Vir Biotechnology beat the EPS estimate in 4 of the last 12 quarters.
Related: VIR income statement, VIR key metrics, VIR chart. See the VIR stock overview for the latest quote and news.
VIR forecast FAQ
What is Vir Biotechnology's price target?
The average analyst price target for Vir Biotechnology is $21.00, 110.8% above the latest close of $9.96.
Is Vir Biotechnology a buy, hold or sell?
Of 9 analysts covering Vir Biotechnology, 6 rate it a strong buy, 3 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Vir Biotechnology's EPS forecast?
Analysts forecast −$1.76 per share for 2026 (range −$2.22 to −$1.37); for 2027 the estimate is −$2.49.
What is Vir Biotechnology's revenue forecast?
The average revenue estimate for 2026 is $245.2 million, growth of 257.7%; for 2027 it is $76.1 million.
When does Vir Biotechnology report earnings?
Vir Biotechnology is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $-0.80.
Does Vir Biotechnology usually beat earnings estimates?
Vir Biotechnology reported EPS at or above the analyst estimate in 4 of the last 12 quarters.